Navigation Links
Affordable anti-rejection drug as effective as higher cost option
Date:10/15/2009

WINSTON-SALEM, N.C. A newer, less expensive drug used to suppress the immune system and prevent organ rejection in kidney and pancreas transplant patients works just as well as its much more expensive counterpart, according to a new study by researchers at Wake Forest University Baptist Medical Center.

Such discoveries are vital in an era of skyrocketing health care costs and debate over health reform, said lead investigator Alan C. Farney, M.D., Ph.D., an associate professor of surgery in the Department of General Surgery, Transplantation Services.

"I think it's very important that the public consider cost, and that they ask their doctors if there are alternatives for them that are less expensive," he said. "Why should we use one drug or intervention over another that is equally effective and a fraction of the cost?"

For the study, published recently in the journal Transplantation, researchers looked at the two most common drugs used for induction immunosuppression therapy with kidney and pancreas transplants:

  • alemtuzumab, a newer drug that costs about $1,000 per single-dose treatment and is marketed under the name CampathTM; and
  • rabbit antithymocyte globulin, which costs about four times more for its multidose treatment than alemtuzumab, and is marketed under the name ThymoglobulinTM.

Both drugs destroy the cells that cause organ rejection during induction immunosuppression therapy a short-term, early treatment meant to rapidly lower the immune system to prevent rejection until the patient begins taking daily drugs to suppress the immune system.

Though more expensive, rabbit antithymocyte globulin has generally been more commonly prescribed than alemtuzumab at Wake Forest Baptist and other transplant centers because there has been a concern that the newer drug would suppress the immune system too much and lead to infections or cancer, Farney said.

"We want to avoid acute rejection, but we also don't want to pay a price when we're trying to do that by leaving the patient over-immunosuppressed," he said. "We were being cautious, but this study reveals that, through at least two years of follow up, both drugs are equally effective and safe."

In the study of 222 patients receiving either kidney transplants alone, simultaneous kidney-pancreas transplants, or pancreas-after-kidney transplants, researchers found that both drugs showed similar survival rates for the patients (96 percent), the transplanted kidneys (89 percent) and the transplanted pancreases (90 percent). The drugs also had similar infection rates.

From Feb. 1, 2005, to Sept. 1, 2007, transplant patients participating in the study received either alemtuzumab or rabbit antithymocyte globulin, followed by the same course of maintenance drugs. Both groups included patients who varied in age, race, gender and risk a unique approach with clinical studies, which usually look at a group with similar characteristics.

The researchers wanted to design this study one of the largest single-institution trials for transplantation drugs to reflect the actual demographics of the Medical Center's transplant patients, Farney said. Transplantation Services at Wake Forest University Baptist Medical Center performs more than 150 kidney and pancreas transplants each year.

"It represents who we really transplant at Wake Forest Baptist," Farney said. "Other trials are so exclusive that you don't know what the true results are for most people."

As a result of the study, the Wake Forest Baptist Transplant Program has adopted the newer drug as part of its standard anti-rejection protocol for kidney and pancreas transplantation, Farney said.


'/>"/>

Contact: Jessica Guenzel
jguenzel@wfubmc.edu
336-716-3487
Wake Forest University Baptist Medical Center
Source:Eurekalert

Related medicine news :

1. Mesoone.com Launches Official Portal With Access To Effective And Affordable Mesotherapy Products
2. Link High Technologies to Offer Allscripts MyWay Affordable Electronic Health Records to NJ Physicians
3. EdOptions(TM) Offers Schools Affordable Solution to Ensure Continuity of Learning
4. Wellcome Trust and Merck launch joint venture to develop affordable vaccines
5. Cash For Crows Feet Program Offers Effective - and Affordable - Laser Skin Treatments
6. Green Parenting is Best for Babys Health and Happiness While Much Easier and Affordable Than Many Parents Know
7. FaxBack Announces New Partner Program to Help Equipment Manufacturers and Service Providers Add Simple and Affordable VoIP Fax Capabilities Into Their Offerings
8. Lets Get it Done! From Coast to Coast, USAction Affiliates Rally This Week for Quality, Affordable Health Care
9. Cost Effective Solution for Patient Testing: Introducing Comprehensive and Affordable Molecular Diagnosis With Verifiable Accuracy
10. MinuteClinic Says Rand Corporation Study in Annals of Internal Medicine Study on Quality, Affordable Care at Retail Clinics Affirms Internal Information
11. Krogers Family of Pharmacies Offer Customers Easy and Affordable Seasonal Flu Vaccinations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & Associates’ ... years of experience in leading technology and human resources operations for health care, ... Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , Innovative Leaders ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. LeRoy Perry’s recently authored whitepaper, ... mobile devices on the billions of users, hundreds of millions of whom are coming ... life threatening, the frequent and common action of looking down at hand-held technology devices ...
(Date:5/26/2016)... ... May 26, 2016 , ... Development Team of Pixel Film Studios ... , "This new layered style transition tool will keep a consistent flow to your ... Pixel Film Studios. , TranSweep is an all new layered style transition tool ...
(Date:5/26/2016)... ON (PRWEB) , ... May 26, 2016 , ... ... Organization, is proud to announce that it has successfully completed another Health Canada ... Branch Inspectorate of Health Canada. The rating resulted from a Good Manufacturing Practices ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... weekend to host their second pop-up shop for three consecutive weekends. The pop-up ... to the Santa Barbara community, a community full of women who appreciate the ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
Breaking Medicine Technology: